Medical School, University of Helsinki, Helsinki, Finland.
Clin Exp Rheumatol. 2014 Jul-Aug;32(4):455-9. Epub 2014 Jun 6.
To evaluate the prevalence of levothyroxine-treated hypothyroidism in rheumatoid arthritis (RA) patients at the time of RA diagnosis in comparison to age- and sex-specific general population. Other objectives were to determine whether the risk of hypothyroidism varies by age at the onset of RA, or by sex or rheumatoid factor (RF) status.
We identified 7,209 incident RA patients diagnosed between January 2004 and December 2007 from a Finnish nationwide register of special reimbursements for medication costs. The presence of hypothyroidism at RA diagnosis was identified from the same register based on special reimbursement decisions for levothyroxine substitution. The prevalence of levothyroxine-treated hypothyroidism was compared to that of an age- and sex-specific Finnish population, and a standardised rate ratio (SRR) for hypothyroidism was calculated.
The SRR for levothyroxine-treated hypothyroidism preceding RA was 1.51 (95% CI 1.35 to 1.67). Neither RF status nor sex modified the risk, although the results did not reach statistical significance among men. The SRR was highest, almost 2.5 among younger female RA patients (20-49 years of age), the excess prevalence of hypothyroidism decreasing steadily and wearing off among patients who were older at the time of diagnosis. The absolute prevalence of hypothyroidism, however, increased with age as it does in the general population.
The risk of hypothyroidism is increased among RA patients already at the disease onset, especially among the young women, regardless of RF status. This calls for attention to screening for hypothyroidism in RA patients, preferably when RA has already been diagnosed.
评估类风湿关节炎 (RA) 患者在确诊 RA 时甲状腺功能减退症(甲减)的患病率,并与特定年龄和性别组的一般人群进行比较。其他目的是确定甲减的风险是否因 RA 发病年龄、性别或类风湿因子 (RF) 状态而异。
我们从芬兰全国药物费用特殊报销登记处确定了 7209 例 2004 年 1 月至 2007 年 12 月期间确诊的新发 RA 患者。根据特殊报销决定,从同一登记处确定了甲减患者的甲减在 RA 诊断时的存在。通过与特定年龄和性别组的芬兰人群进行比较,评估了甲状腺素替代治疗的甲减患病率,并计算了甲减的标准化发病比 (SRR)。
RA 发病前的甲状腺素替代治疗甲减的 SRR 为 1.51(95%CI 1.35 至 1.67)。RF 状态和性别均未改变风险,尽管在男性中结果未达到统计学意义。SRR 在年轻女性 RA 患者中最高(20-49 岁),接近 2.5,随着诊断时年龄的增加,甲减的超额患病率逐渐下降。然而,与一般人群一样,甲减的绝对患病率会随着年龄的增长而增加。
RA 患者在疾病发病时就已经存在甲减风险,尤其是年轻女性,无论 RF 状态如何。这呼吁关注 RA 患者的甲减筛查,最好在已经诊断出 RA 时进行。